DEA/OD/ODE
Introduction:
5-methoxy-N,N-diisopropyltryptamine
(5-MeO-DIPT) is a tryptamine derivative and shares many
similarities with schedule I tryptamine hallucinogens such as
alpha-ethyltryptamine, N,N-dimethyltryptamine,
N,N-diethyltryptamine, bufotenine, psilocybin and psilocin.
Since 1999, there has been a growing popularity of 5-MeO-DIPT
among drug abusers. This substance is abused for its
hallucinogenic effects.
Licit Uses:
5-MeO-DIPT has no approved
medical uses in the United States.
Chemistry/Pharmacology:
5-MeO-DIPT is a tryptamine
derivative. The hydrochloride salt of 5-MeO-DIPT is a white
crystalline powder. In animal behavioral studies, 5-MeO-DIPT has
been shown to produce behavioral effects that are substantially
similar to those of
1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and
lysergic acid diethylamide (LSD), both schedule I hallucinogens.
In humans, 5-MeO-DIPT
elicits subjective effects including hallucinations similar to
those produced by several schedule I hallucinogens such as 2C-B
and 4-ethyl-2,5-dimethoxyphenyl-isopropylamine (DOET). The
threshold dose of 5-MeO-DIPT to produce psychoactive effects is
4 mg, while effective doses range from 6 to 20 mg. 5-MeO-DIPT
produces effects with an onset of 20 to 30 minutes and with peak
effects occurring between 1 to 1.5 hours after administration.
Effects last about 3 to 6 hours. Initial effects include mild
nausea, muscular hyperreflexia, and dilation of pupils. Other
effects include relaxation associated with emotional
enhancement, talkativeness and behavioral disinhibition. High
doses of 5-MeO-DIPT produce abstract eyes-closed imagery.
5-MeO-DIPT alters sensory perception and judgment and can pose
serious health risks to the user and the general public. Abuse
of 5-MeO-DIPT led to at least one emergency department
admission.
Illicit Uses:
5-MeO-DIPT is abused for
its hallucinogenic-like effects and is used as a substitute for
MDMA. It is often administered orally as either powder, tablets
or capsules at doses ranging from 6-20 mg. Other routes of
administration include smoking and snorting. Tablets often bear
imprints commonly seen on MDMA tablets (spider and alien head
logos) and vary in color. Powder in capsules was found to vary
in colors.
User Population:
Youth and young adults are
the main abusers of 5-MeO-DIPT.
Illicit Distribution:
According to the System to
Retrieve Information from Drug Evidence (STRIDE) data, since
2001, DEA forensic laboratories analyzed 73 drug exhibits from
38 law enforcement cases pertaining to the trafficking,
distribution and abuse of 5-MeO-DIPT. The analyzed exhibits
comprised of about 12,207 tablets, 579 capsules, and 6,537.93 gm
powder.
According to National
Forensic Laboratory Information System (NFLIS), state and local
forensic laboratories analyzed 43 5-MeO-DIPT drug items from 36
different law enforcement cases during 1999 through 2006.
According to STRIDE and
NFLIS, 5-MeO-DIPT has been encountered in a number of states
including Arizona, Arkansas, California, Delaware, District of
Columbia, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana,
Maine, Maryland, Massachusetts, Minnesota, Nevada, New Jersey,
New Mexico, New York, Oregon, Pennsylvania, Texas, Virginia,
Washington and Wisconsin. 5-MeO-DIPT has been illicitly
available from United States and foreign chemical companies and
from individuals through the Internet. There is some evidence of
the attempted clandestine production of 5-MeO-DIPT.
Control Status:
The Drug Enforcement
Administration (DEA) placed 5-MeO-DIPT temporarily in schedule I
of the Controlled Substances Act (CSA) on April 4, 2003,
pursuant to the temporary scheduling provisions of the CSA (68
FR 16427). On September 29, 2004, 5-MeO-DIPT was controlled as
schedule I substance under the CSA (69 FR 58050).
Comments and additional information are
welcomed by the Drug and Chemical Evaluation Section, FAX
202-353-1263 or telephone 202-307-7183.